IL132596A0 - Vector - Google Patents

Vector

Info

Publication number
IL132596A0
IL132596A0 IL13259698A IL13259698A IL132596A0 IL 132596 A0 IL132596 A0 IL 132596A0 IL 13259698 A IL13259698 A IL 13259698A IL 13259698 A IL13259698 A IL 13259698A IL 132596 A0 IL132596 A0 IL 132596A0
Authority
IL
Israel
Prior art keywords
vector
noi
poi
tumour
interest
Prior art date
Application number
IL13259698A
Other languages
English (en)
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132596(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9711579.4A external-priority patent/GB9711579D0/en
Priority claimed from GBGB9713150.2A external-priority patent/GB9713150D0/en
Priority claimed from GBGB9714230.1A external-priority patent/GB9714230D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of IL132596A0 publication Critical patent/IL132596A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Analysis (AREA)
IL13259698A 1997-06-04 1998-06-04 Vector IL132596A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711579.4A GB9711579D0 (en) 1997-06-04 1997-06-04 Therapeutic genes
GBGB9713150.2A GB9713150D0 (en) 1997-06-20 1997-06-20 Fusion proteins
GBGB9714230.1A GB9714230D0 (en) 1997-07-04 1997-07-04 Therapeutic genes
PCT/GB1998/001627 WO1998055607A2 (fr) 1997-06-04 1998-06-04 Vecteur

Publications (1)

Publication Number Publication Date
IL132596A0 true IL132596A0 (en) 2001-03-19

Family

ID=27268875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13259698A IL132596A0 (en) 1997-06-04 1998-06-04 Vector

Country Status (16)

Country Link
US (6) US6852703B1 (fr)
EP (2) EP1717248A1 (fr)
JP (3) JP2002507117A (fr)
CN (1) CN1224712C (fr)
AT (1) ATE444358T1 (fr)
AU (1) AU747602B2 (fr)
CA (1) CA2292760A1 (fr)
CY (1) CY1109686T1 (fr)
DE (1) DE69841204D1 (fr)
DK (1) DK1012259T3 (fr)
ES (1) ES2332435T3 (fr)
IL (1) IL132596A0 (fr)
NO (1) NO995901L (fr)
NZ (1) NZ500633A (fr)
PT (1) PT1012259E (fr)
WO (1) WO1998055607A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
AU1290001A (en) 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (fr) 2001-10-02 2006-04-19 Inst Clayton De La Rech Procedes et compositions se rapportant a des vecteurs lentiviraux a expression reduite et leurs applications
EP1450857B1 (fr) * 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
US20040241703A1 (en) * 2002-08-19 2004-12-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7939059B2 (en) * 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003092630A2 (fr) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification d'anticorps monoclonaux humains largement neutralisants a reaction croisee au moyen d'un procede d'adherence sequentielle sur plaque d'antigenes de banques de presentation du phage
US7566451B2 (en) * 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
AU2003241006B2 (en) 2003-05-21 2011-03-24 Ares Trading S.A. TNF-like secreted protein
EP1621550A1 (fr) * 2004-07-29 2006-02-01 Dompé S.P.A. Cellules ciblant des tumeurs, exprimant la protéine "tumor necrosis factor-related apoptosis inducing ligand" (TRAIL)
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
CA2578131A1 (fr) * 2004-09-10 2006-03-23 Wyeth Anticorps anti-5t4 humanises et conjugues anticorps anti-5t4/calicheamicine
WO2006044410A2 (fr) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Proteines hybrides comprenant l'anticorps monoclonal a32, utiles comme inhibiteurs du vih et vaccins anti-vih
CA2585574A1 (fr) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Anticorps monoclonaux humains a reaction antigenique croisee large neutralisant generalement vih-1
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN101506235B (zh) 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
EP2076287A2 (fr) * 2006-10-12 2009-07-08 Wyeth Procédés et compositions ayant une opalescence réduite
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769326A1 (fr) * 2009-07-27 2011-02-10 Baxter International Inc. Conjugues de proteine de coagulation sanguine
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
CA2822591C (fr) 2010-12-22 2020-12-29 Baxter International Inc. Materiels et methodes pour la conjugaison d'un derive d'acide gras soluble dans l'eau a une proteine
JP2014533929A (ja) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ５ｔ４およびｃｄ３に対する二重特異的結合性分子
US9265969B2 (en) * 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
RU2646498C2 (ru) 2012-01-24 2018-03-05 Пфайзер Инк. Способы детектирования 5Т4-положительных циркулирующих опухолевых клеток и способы диагностики 5Т4-положительного рака у млекопитающего
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2014043518A1 (fr) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine brachyury, vecteurs non levure, non poxvirus, codant pour la protéine brachyury, et leur utilisation
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP3046583B1 (fr) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Conjugués de pseudo-particules virales destinés au traitement de tumeurs
WO2016071758A1 (fr) 2014-11-03 2016-05-12 Leiden University Medical Center Récepteurs de cellules t dirigées contre bob1 et leurs utilisations
CA2978171A1 (fr) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg Recepteurs de lymphocytes t diriges contre l'antigene exprime de preference dans le melanome, et leurs utilisations
KR20180057610A (ko) 2015-08-03 2018-05-30 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도
EP3184547A1 (fr) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation
EP3368559A4 (fr) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. Compositions et méthodes pour le du traitement du cancer
KR20180083868A (ko) * 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
CN108473950A (zh) * 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR102609624B1 (ko) 2017-03-15 2023-12-05 옥스포드 바이오메디카(유케이) 리미티드 방법
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
KR20200129108A (ko) 2018-03-08 2020-11-17 페인스 테라퓨틱스 인코포레이티드 항-tip-1 항체 및 이의 용도
CA3093745A1 (fr) 2018-03-12 2019-09-19 Genmab A/S Anticorps

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0403559A1 (fr) * 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Ameliorations dans le domaine des antigenes
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
CA2016897A1 (fr) 1989-05-17 1990-11-17 John W. Wills Secretion de produits recombinants sous l'influence de retrovirus
WO1991000047A1 (fr) 1989-06-30 1991-01-10 The Regents Of The University Of California Detection de retrovirus
WO1992000092A1 (fr) 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand pour recepteur a cd28 sur des lymphocytes b et procedes
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5439654A (en) 1994-03-10 1995-08-08 Steris Corporation Cutter for opening sterilant reagent cups
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP0706799B1 (fr) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugués
WO1996009400A1 (fr) 1994-09-19 1996-03-28 Systemix, Inc. Procedes permettant de modifier genetiquement des cellules souches hematopoietiques
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (fr) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Polypeptide d'enveloppe virale modifie
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
CA2234931C (fr) * 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Nouveaux vecteurs d'expression et procedes d'utilisation correspondants
WO1997017090A1 (fr) * 1995-11-07 1997-05-15 Baylor College Of Medicine Production induite par des adenovirus de proteines bioactives dans des cellules de mammiferes ou d'animaux
JP2000500013A (ja) 1995-11-08 2000-01-11 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
IL132596A0 (en) * 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
DE19724502C1 (de) 1997-06-11 1998-10-08 Webasto Thermosysteme Gmbh Heizgerät
EP1104462B1 (fr) * 1998-08-10 2007-01-03 Agensys, Inc. Bpc-1: proteine secretee, specifique du cerveau, exprimee et secretee par des cellules cancereuses de la prostate et de la vessie
AU1290001A (en) * 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle

Also Published As

Publication number Publication date
US6852703B1 (en) 2005-02-08
ATE444358T1 (de) 2009-10-15
NO995901D0 (no) 1999-12-02
JP2009153524A (ja) 2009-07-16
EP1717248A1 (fr) 2006-11-02
AU7780198A (en) 1998-12-21
JP2011000122A (ja) 2011-01-06
US20110065173A1 (en) 2011-03-17
US20060286634A1 (en) 2006-12-21
US8084249B2 (en) 2011-12-27
PT1012259E (pt) 2009-11-06
US20090017532A1 (en) 2009-01-15
NO995901L (no) 2000-02-04
EP1012259A2 (fr) 2000-06-28
US7531648B2 (en) 2009-05-12
US7718627B2 (en) 2010-05-18
CY1109686T1 (el) 2014-08-13
EP1012259B1 (fr) 2009-09-30
CN1258319A (zh) 2000-06-28
US20030018004A1 (en) 2003-01-23
WO1998055607A2 (fr) 1998-12-10
WO1998055607A3 (fr) 1999-03-04
ES2332435T3 (es) 2010-02-04
JP2002507117A (ja) 2002-03-05
NZ500633A (en) 2002-10-25
AU747602B2 (en) 2002-05-16
CN1224712C (zh) 2005-10-26
DK1012259T3 (da) 2010-01-18
CA2292760A1 (fr) 1998-12-10
US20050032216A1 (en) 2005-02-10
DE69841204D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
IL132596A0 (en) Vector
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
IL110284A0 (en) Viral vectors and their use in gene therapy
EP0650722A3 (fr) Particules d'invasion enrobées d'une protéine.
PL309403A1 (en) Modified cutinases, dna, vector and host
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
HU9503194D0 (en) Novel sunsscreens, photoprotective cosmetic compositions containing them and uses thereof
EP0237045A3 (en) Dna encoding flagellin and vector having the same
HU9503192D0 (en) Novel sunscreens, photoprotective cosmetic compositions containing them and uses thereof
PL309388A1 (en) Modified cutinases, dna, vector and host
GB8911435D0 (en) Bacillus thuringiensis transformation
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
ZA879011B (en) Variants of hirudin,their use and their preparation
EP0363436A4 (fr) Genes clones de variantes de la proteine g et variantes de la proteine g exprimees par ces genes.
EP0672153A4 (fr) Vecteur transportant et exprimant un gene etranger.
EP0412797A3 (en) The therapeutic use of substituted benzenes, formulations thereof and novel substituted benzenes
AU2415599A (en) Rantes mutants and therapeutic applications thereof
EP0919621A4 (fr) Tak1 humaine et adn codant celle-ci
AU119245S (en) Decorator's hand tool
GB9604518D0 (en) Novel compounds
GB9710636D0 (en) Novel mixture
Ito Studies on the processing of the exported proteins in Bacillus subtilis
Gharavi Molecular cloning of the human lipoxygenase gene
KR950002801U (ko) 리 메니큐어(LEE＇S Manicure)
EP0200512A3 (en) Peptides and their use in therapy